Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with prader-labhard-willi syndrome

M. Cappa, A. Grossi, P. Borrelli, D. Ghigo, J. Bellone, S. Benedetti, D. Carta, S. Loche

Research output: Contribution to journalArticle

Abstract

We evaluated the GH response to combined administration of pyridostigmine (PD), a cholinergic agonist, and GH-releasing hormone (GHRH) (60 mg PD given orally 60 min before the GHRH bolus) as well as baseline IGF-I concentrations in 10 patients (5 males and 5 females, age 6.0–24 years) with Prader- Labhard-Willi (PLW) syndrome, 8 prepubertal obese children (4 males and 4 females, age 5.6-12.0 years) and 9 prepubertal short normal children (7 males and 2 females, age 8.0-12.8 years). Mean GH responses to PD + GHRH were significantly lower (p <0.0001) in the PLW patients (13.8 ± 3.3 μg/l) than in the short normal children (52.2 ± 9.0 μg/l) and similar to those of the obese children (14.3 ± 3.2 μg/l). Mean serum IGF-I levels were significantly lower (p <0.05) in the PLW patients (117.5 ± 26.4 μg/l) than in the obese (329.3 ± 88.0 μg/l) and the short normal children (214.3 ± 38.3 μg/l). Two of the PLW patients had absent GH responses to PD + GHRH associated with subnormal IGF-I concentrations, indicating pituitary GH deficiency. When these 2 cases were excluded from the statistical calculation, mean peak GH responses to PD + GHRH remained significantly lower (p <0.0001) in the PLW patients (17.1 ± 3.0 μg/l), while their mean serum IGF-I concentrations (143.4 ± 71.5 μg/l) were not significantly different from those of the other two groups. These results indicate that patients with the PLW syndrome have a reduced or absent GH secretory reserve associated in some cases with low levels of IGF-I, Whether these findings are involved in the pathogenesis of their short stature remains to be confirmed.

Original languageEnglish
Pages (from-to)51-55
Number of pages5
JournalHormone Research in Paediatrics
Volume39
Issue number1-2
DOIs
Publication statusPublished - 1993

Keywords

  • Growth hormone
  • Growth hormone-releasing hormone
  • Obesity
  • Prader-Labhard-Willi
  • Pyridostigmine

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with prader-labhard-willi syndrome'. Together they form a unique fingerprint.

  • Cite this